Archive | New Zealand Approval

Melanoma New Zealand delighted with KEYTRUDA registration

Melanoma New Zealand is delighted that anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) has been approved by Medsafe and is now a registered medicine in New Zealand. Chief Executive Officer of Melanoma New Zealand, Linda Flay, says: “This is an important step for New Zealanders. Along with Australia, we have the highest incidence of melanoma in the world […]

Read the full story

Posted in Cancer in the News, New Zealand Approval


Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories